Скачать или смотреть Cell Therapy: Off-the-Shelf CAR γδT Cells Generated Using CRISPR/AAV

Speaker: Meisam Naeimi, DVM, PhD

In this Webinar, You Will Learn:
The importance of off-the-shelf CAR-T cells in making therapies more affordable and accessible
Next-generation engineering: the development of CRISPR/AAV-based off-the-shelf CAR γδT cells to overcome the limitations of traditional CAR-T therapies
Preclinical efficacy: the potent antitumor activity of CAR γδT cells demonstrated across multiple tumor types

About Meisam Naeimi, DVM, PhD:
Dr. Meisam Naeimi’s mission is to bring cellular therapies to low- and middle-income countries. At Nationwide Children’s Hospital and The Ohio State University, he leads a translational research program focused on gene-edited T and γδT cell therapies for high-grade gliomas, T-ALL, and other hard-to-treat malignancies. He currently serves as Chief Scientific Officer at CARTx Therapeutics, where he drives the development of next-generation allogeneic CAR γδT cell therapies for both pediatric and adult cancers.

Dr. Naeimi has pioneered CRISPR/AAV-based engineering platforms to generate potent off-the-shelf CAR γδT cells, including CD38-, GD2-, and Nucleolin-directed constructs, and has advanced multiple collaborations to scale these therapies globally. His work bridges academic innovation with industry translation, supported by a strong track record in preclinical development, grant funding, and strategic partnerships.